|1.||Lai, Chih-Chia: 2 articles (11/2009 - 07/2007)|
|2.||Sarkaria, J N: 1 article (05/2014)|
|3.||Furnari, F B: 1 article (05/2014)|
|4.||Cavenee, W K: 1 article (05/2014)|
|5.||Vuori, K: 1 article (05/2014)|
|6.||Hu, B: 1 article (05/2014)|
|7.||Feng, H: 1 article (05/2014)|
|8.||Cheng, S-Y: 1 article (05/2014)|
|9.||Zhang, Haipeng: 1 article (03/2012)|
|10.||Zhu, Wenbo: 1 article (03/2012)|
02/01/2008 - "KT 5720, a specific inhibitor of protein kinase A (PKA), did not show any effect on low-dose morphine-induced hyperalgesia. "
11/27/2009 - "We found that the potentiating effect of CARTp on spinal NMDA-induced hyperalgesia in rats was reduced by intrathecal pretreatment with KT5720 (a selective PKA inhibitor) or GF109206X (a selective PKC inhibitor), but was increased by pretreatment with calyculin A (a protein phosphatase inhibitor). "
06/30/2006 - "KT5720, a selective inhibitor of cAMP-dependent protein kinase, reduced the calcium transients induced by capsaicin or the other, much more potent transient receptor potential vanilloid type 1 receptor agonist resiniferatoxin in trigeminal sensory neurons and diminished the drop of the noxious heat threshold (heat allodynia) evoked by intraplantar resiniferatoxin injection. "
03/01/2012 - "In the cAMP elevator cholera toxin-induced differentiation model of rat C6 glioma cells, miR-335 was significantly up-regulated, which was mimicked by other typical cAMP/PKA pathway activators (e.g., forskolin, dibutyryl-cAMP) and abolished by PKA-specific inhibitor (9R,10S,12S)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i] [1,6]benzodiazocine-10-carboxylic acid, hexyl ester (KT5720). "
10/15/2003 - "However, KT5720, a selective PKA inhibitor, reduced neither anti-Fas-triggered nor glioma-associated IL-10 expression. "
05/08/2014 - "Treatments of glioma cells using the PKA inhibitors H-89 and KT5720, overexpression of a PKA inhibitor (PKI), and in vitro PKA kinase assays show that EGFRvIII induction of serine phosphorylation of Dock180 is PKA-dependent. "
05/01/2009 - "Inhibition of PKA by KT5720 abolished the protective effect of AM/AMBP-1 on hypoxia-induced apoptosis. "
12/01/2005 - "Hypoxia-induced increase in KIR currents was abolished by the PKA inhibitors, Rp-8-(4-chlorophenylthio)-cAMPs (10 microM) and KT-5720 (1 microM). "
01/05/2001 - "The hypoxia-induced acidification was attenuated by protein kinase C inhibitors, calphostin C and chelerythrine, but not by a protein kinase A inhibitor, KT5720. "
04/29/2005 - "In human MG63 cells, however, we found that ROS promoted heat shock factor 2 (HSF2) binding to heat shock element in human RANKL promoter region and that HSF2, but not PKA, was required for ROS up-regulation of RANKL as revealed by KT5720 and HSF2 RNA interference transfection. "
11/01/2008 - "Unresponsiveness to hyperosmotic shock represented inhibition of NHE3 activity, and was prevented using the protein kinase A inhibitor KT5720. "
09/01/1997 - "Retrograde amnesia was induced in rats trained in step-down inhibitory avoidance by four different treatments: an ip injection of beta-endorphin (1.0 microgram kg), an electroconvulsive shock (ECS), an intrahippocampal infusion of the calcium/calmodulin protein kinase II inhibitor, KN62 (0.08 microgram/side), given 0 h after training, or an intrahippocampal infusion of the protein kinase A inhibitor, KT5720 (0.5 microgram/side), given 3 h after training. "
08/01/1997 - "When given 3 or 6 h post-training, 8-Br-cAMP, forskolin, SKF38393, norepinephrine and NAN-190 caused memory facilitation, while KT5720, SCH23390, timolol and 8-OH-DPAT caused retrograde amnesia. "
|1.||Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)
|2.||protein kinase modulator
|3.||N- (2- (4- bromocinnamylamino)ethyl)- 5- isoquinolinesulfonamide (h89)
|4.||Protein Kinase Inhibitors
|6.||Staphylococcal Protein A (A, Protein)
|8.||Protein Kinase C
|10.||Morphine (MS Contin)
|1.||Vagus Nerve Stimulation